Medicus Pharma Ltd. Common Stock Total Liabilities
Medicus Pharma Ltd. Common Stock total liabilities. Based on the latest financial reports, Medicus Pharma Ltd. Common Stock (MDCX) has total liabilities worth $20.33 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See MDCX defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Medicus Pharma Ltd. Common Stock (2010–2025)
Total liabilities of Medicus Pharma Ltd. Common Stock from 2010 to 2025. This chart illustrates how Medicus Pharma Ltd. Common Stock's total liabilities have evolved over time, based on quarterly financial data.
Medicus Pharma Ltd. Common Stock Competitors by Total Liabilities
The table below lists competitors of Medicus Pharma Ltd. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Renew Holdings plc
LSE:RNWH
|
UK | GBX328.01 Million |
|
CLASS 1 NICKEL+TECH.LTD
F:77C
|
Germany | €2.86 Million |
|
Pivotal Metals Ltd
AU:PVT
|
Australia | AU$279.63K |
|
ECOUP OYJ EO 1
F:62H
|
Germany | €12.21 Million |
|
The House of Agriculture Spiroy S.A.
AT:SPIR
|
Greece | €29.15 Million |
|
Aspire BioPharma, Inc.
NASDAQ:ASBP
|
USA | $1.78 Million |
|
Boa Concept SA
PA:ALBOA
|
France | €16.02 Million |
|
REC Silicon ASA
OL:RECSI
|
Norway | Nkr582.30 Million |
Liability Composition Analysis (2010–2025)
This chart breaks down Medicus Pharma Ltd. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Medicus Pharma Ltd. Common Stock (MDCX) total assets.
Liquidity & Leverage Metrics
Medicus Pharma Ltd. Common Stock Total Liabilities Ratios Explained
Medicus Pharma Ltd. Common Stock total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.57 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -16.35 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Medicus Pharma Ltd. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Medicus Pharma Ltd. Common Stock (2010–2025)
The table below shows the annual total liabilities of Medicus Pharma Ltd. Common Stock from 2010 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $10.02 Million | +299.02% |
| 2024-12-31 | $2.51 Million | +221.41% |
| 2023-12-31 | $781.61K | -93.74% |
| 2022-12-31 | $12.48 Million | +17.92% |
| 2021-12-31 | $10.58 Million | +10152.60% |
| 2017-12-31 | $103.23K | +1024.19% |
| 2016-12-31 | $9.18K | +168.82% |
| 2015-12-31 | $3.42K | -99.93% |
| 2010-12-31 | $5.00 Million | -- |
About Medicus Pharma Ltd. Common Stock
Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin. The company has a strategic collaboration with the Gorlin Syndrome Alliance to access to SKINJECT in Patients with Gorlin Syndrome. The com… Read more